Function of dopamine receptors in Parkinson's disease: prolactin responses.
In 64 patients with Parkinson's disease (PD), the basal level of prolactin (PRL) was normal. Bromocriptine (BCT) caused a significant suppression of PRL in all parkinsonian patients and controls. When given after BCT treatment, thyrotropin-releasing hormone (TRH) induced a significantly lower PRL rise in recent-onset parkinsonian patients than in controls or advanced patients. In advanced parkinsonian patients with daily fluctuations in disability, the corresponding TRH-induced PRL response was significantly higher than in controls. In advanced parkinsonian patients without fluctuations, the PRL response to TRH was almost the same as in controls.
Laihinen
A
A
Rinne
U K
UK
D000368:Aged; D001971:Bromocriptine / Q000494:pharmacology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000378:metabolism*; D011388:Prolactin / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000378:metabolism*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology; D013997:Time Factors
D011954:Receptors, Dopamine; D001971:Bromocriptine; D007980:Levodopa; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin